肝胆相照论坛

标题: Aligos Therapeutics报告2020年第四季度和全年财务业绩以及近期业 [打印本页]

作者: StephenW    时间: 2021-3-24 11:30     标题: Aligos Therapeutics报告2020年第四季度和全年财务业绩以及近期业

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Aligos Therapeutics
Wed, March 24, 2021, 7:05 AM·11 min read

- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021
- Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initial Public Offering (IPO), inclusive of the underwriters’ exercise of their overallotment option
- Cash, Cash Equivalents and investments of $243.5 million as of December 31, 2020

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2020 and provided an overview of recent business highlights.

"Last year was a transformative year for Aligos,” said Larry Blatt, PhD, MBA, CEO of Aligos. “During 2020, we became both a well-financed public company, via our $167.2 million IPO, as well as a clinical stage company by advancing our first two CHB assets, ALG-010133 and ALG-000184, into the clinic. This year is on track to be similarly impactful for Aligos as we expect to generate important proof of activity data in CHB patients for both ALG-010133 and ALG-000184 as well as advancing two more assets, ALG-020572 and ALG-055009, into the clinic.”

“The advancement of these four drug candidates towards and in the clinic this year represents the culmination of three years of hard work by all of our employees,” noted Leo Beigelman, PhD, President of Aligos. “We look forward to seeing the clinical results of these efforts.”

Recent Business Highlights

Aligos Portfolio of Drug Candidates:

    ALG-010133 (an S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) molecule that is designed to decrease hepatitis B surface antigen (HBsAg) levels)

        Single and multiple ascending dose (SAD/MAD) evaluation in healthy volunteers (HV) was completed generating data supportive of commencing dosing in CHB patients.

        Enrollment of CHB patients is ongoing. The study is evaluating 12 weeks of once weekly subcutaneous ALG-010133/placebo dosing in virologically suppressed CHB patients. Safety and antiviral data from the initial cohort(s) is expected in the second half of 2021.

    ALG-000184 is a small molecule class II capsid assembly modulator (CAM) that is designed to target hepatitis B virus (HBV) capsid assembly, resulting in decreased HBV DNA/RNA levels, as well as the establishment of covalently closed circular DNA (cccDNA)

        SAD/MAD evaluation in HV was completed generating data supportive of commencing dosing in CHB patients.

        Screening in CHB patients has commenced. The study is evaluating 28 days of once daily oral dosing of ALG-000184 or placebo in treatment naïve/currently not treated patients. Safety and antiviral data from the initial cohort(s) expected in the second half of 2021.

    ALG-020572 (antisense oligonucleotide (ASO) that is designed to decrease HBsAg levels)

        Advanced into clinical trial application (CTA)-enabling toxicology studies. Planned to begin Phase 1 study in the second half of 2021.

    ALG-055009 (thyroid hormone beta agonist that is designed to reduce plasma and liver lipid levels in nonalcoholic steatohepatitis (NASH))

        Advanced into CTA-enabling toxicology studies. Planned to begin Phase 1 study in the second half of 2021.

    ALG-125755 (small interfering RNA (siRNA) that is designed to decrease HBsAg levels)

        Drug candidate identified and advancing into nonclinical studies. CTA-enabling toxicology studies planned for the second half of 2021.
作者: StephenW    时间: 2021-3-24 11:31

Aligos Therapeutics报告2020年第四季度和全年财务业绩以及近期业务亮点

Aligos治疗学
2021年3月24日,星期三,上​​午7:05·11分钟阅读

-先进的ALG-010133和ALG-000184进入临床-预计都将在2021年为慢性乙型肝炎(CHB)患者生成安全性和抗病毒活性数据
-在纳斯达克全球精选市场上市,股票代码为ALGS,通过首次公开募股(IPO)筹集了1.672亿美元的总收益,其中包括承销商行使的超额配股权
-截至2020年12月31日的现金,现金等价物和投资为2.435亿美元

2021年3月23日,加利福尼亚州南旧金山-全球领先的生物制药公司Aligos Therapeutics,Inc.(纳斯达克股票代码:ALGS)今天致力于开发新型疗法,以满足未满足的病毒和肝病医疗需求。公布了2020年第四季度和全年的财务业绩,并概述了近期的业务亮点。

“去年是Aligos转型的一年,” Aligos首席执行官Larry Blatt博士说:“到2020年,我们通过1.672亿美元的IPO成为资金雄厚的上市公司以及一家临床阶段的公司通过将我们的前两个CHB资产ALG-010133和ALG-000184推入临床,今年有望对Aligos产生同样的影响,因为我们希望能够为ALG-010133和CHS患者生成CHB患者活动数据的重要证据ALG-000184,以及将另外两个资产ALG-020572和ALG-055009推入诊所。”

Aligos总裁Leo Beigelman博士说:“这四种候选药物在今年和将来在诊所中的进步代表了我们全体员工三年辛勤工作的结晶。” “我们期待看到这些努力的临床结果。”

最近的业务亮点

Aligos候选药物产品组合:

    ALG-010133(一种抑制S抗原转运的寡核苷酸聚合物(STOPS™)分子,旨在降低乙型肝炎表面抗原(HBsAg)的水平)

        完成了健康志愿者(HV)的单次和多次递增剂量(SAD / MAD)评估,生成了支持CHB患者开始给药的数据。

        CHB患者的入组正在进行中。这项研究评估了在病毒学抑制的CHB患者中每周一次皮下注射ALG-010133 /安慰剂的12周剂量。预计到2021年下半年,来自最初队列的安全性和抗病毒数据。

    ALG-000184是设计用于靶向乙型肝炎病毒(HBV)衣壳装配的小分子II类衣壳装配调节剂(CAM),导致HBV DNA / RNA水平降低以及共价闭合环状DNA(cccDNA)的建立)

        HV中的SAD / MAD评估已完成,生成了支持CHB患者开始用药的数据。

        已经开始对CHB患者进行筛查。该研究正在评估初次/目前未治疗的患者中每天口服口服ALG-000184或安慰剂的28天。预计2021年下半年来自最初队列的安全性和抗病毒数据。

    ALG-020572(旨在降低HBsAg水平的反义寡核苷酸(ASO))

        进入可进行毒理学研究的临床试验应用(CTA)。计划于2021年下半年开始第一阶段研究。

    ALG-055009(旨在降低非酒精性脂肪性肝炎(NASH)中血浆和肝脂质水平的甲状腺激素β激动剂)

        进入支持CTA的毒理学研究领域。计划于2021年下半年开始第一阶段研究。

    ALG-125755(旨在降低HBsAg水平的小干扰RNA(siRNA))

        确定了候选药物并进入非临床研究。支持CTA的毒理学研究计划于2021年下半年进行。
作者: StephenW    时间: 2021-3-24 11:31

https://finance.yahoo.com/news/a ... rter-200500613.html




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5